Orbis Biosciences, Inc. has granted Daré Bioscience, Inc. an exclusive option to license worldwide rights to Orbis’ long-acting contraceptive products. This agreement leverages Orbis’ Stratµm technology to create an etonogestrel contraceptive for six and 12-month durations.
The agreement includes pre-clinical studies and the option to enter into a license agreement for clinical development. Financial terms were not disclosed.
“Our long-acting contraceptive products were developed to fill a gap in the options currently available to women. We are excited by Daré’s commitment to developing novel women’s health products,” said Maria Flynn, CEO and president of Orbis Biosciences.
“Orbis’s products fit Daré’s commitment to advance innovative products for women’s reproductive health. We are dedicated to finding the best products and cultivating them for the United States’contraceptive and sexual-health needs,” said Sabrina Martucci Johnson, president and CEO of Daré Bioscience.